^
Association details:
| Biomarker: | SDC1 positive |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | bortezomib (Proteasome inhibitor) + BTX306 (Protein homeostatic modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance
Published date:
07/06/2020
Excerpt:
Finally, BTX306 demonstrated strong activity against primary CD138-positive plasma cells, showed enhanced anti-proliferative activity in combination with bortezomib and dexamethasone, and was effective in an in vivo systemic model of multiple myeloma.
Secondary therapy:
dexamethasone
DOI:
10.1007/s00109-020-01943-6
